Status:
COMPLETED
STAMP+CBT mHealth for Cancer Pain
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborating Sponsors:
National Palliative Care Research Center
Conditions:
Active Cancer
Active Cancer Treatment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to test whether a mobile application developed to help people with cancer pain is useful and helpful to patients with cancer.
Detailed Description
This research study involves the use of a smartphone app at home in addition to surveys and potentially an interview at the end of the study. The research study procedures include screening for eligi...
Eligibility Criteria
Inclusion
- \- PILOT COHORT
- Age ≥ 18 years
- Patients diagnosed with an active cancer diagnosis, either undergoing active cancer treatment or receiving treatment for an advanced cancer or are receiving palliative care
- Treatment managed at participating clinic (DFCI outpatient palliative care, gastrointestinal cancer center, and DFCI satellite clinic Merrimack Valley or Londonderry)
- Chronic pain related to cancer or treatment (\> pain score of 4)
- Has an active prescription for at least one opioid medication to treat their cancer pain (i.e. not for post-surgical pain)
- Own a compatible smartphone (android) or is willing to use an android device provided by the study team
- Completes baseline survey
Exclusion
- Patients in survivorship: patients who have completed their treatment regimens, are not actively receiving treatment for an advanced cancer, or have a cancer that is in remission
- Cognitive impairment that would interfere with study participation, as judged by treating clinician
- Inability to speak English: the intervention has not yet been translated to Spanish
- History of opioid use disorders
- Enrolled in hospice
- Currently hospitalized
- Use of transmucosal fentanyl, given safety concerns and ongoing risk mitigation program required to prescribe these (TIRF REMS).
- Pain primarily related to a recent surgery
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 27 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05403801
Start Date
July 1 2022
End Date
June 27 2023
Last Update
January 1 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
2
Dana-Farber at Merrimack Valley
Methuen, Massachusetts, United States, 01844
3
Dana-Farber at Londonderry
Londonderry, New Hampshire, United States, 03053